LUPRON INJ *
Manufacturer Details
TAP PHARMA INC
Compositions:
Leuprolide acetate 5mg/ml inj,
|
Strength
|
Rate
|
Packing Style
|
|
5mg/ml
|
0.00
|
Tab
|
List of Related Indications:
- Prostatic cancer-advanced cond
List Of Drugs:
- Leuprolide acetate- @Gonadotropin Hormone analog- (Dec 1997)
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
Drug/Lab test interactions:
Since leuprotide suppresses the pituitary -gonadal system, diagnostic tests o f pituitary gonodotropic and gonadol functions during treatment and upto 12 weeks after discontinuing depot may be misleading.
Indication:
Advanced prostatic cancer
Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Leuprololide Acetate Anti-cancer December 1997
Depot Inj
Patent Expiry Date of drugs (Ref - IDMA Publication)
Chemical Category Manufacturer/ US Patent
Ingredient- Marketer Expiration Date
Leuprolide Cancer/ TAP Holdings 01-11-2004
acetate Oncology
Adverse Reaction:
ECG changes, high blood pressure, edema, Insomnia, sleep disorders, Pain, headache, Dizziness, light headedness, Hot flushes, Nausea, vomiting, Bone pain, Urinary frequency/urgency/ disorders hematuria, Urinary tract infection, Anemia, Asthenia
Contra-Indications:
Pregnancy, lactation.
Special precautions:
Flare phenomenon, to reduce risk of flare in initial therapy an anti-androgen may be administered 3 days before therapy and continued for 2-3 weeks Patients at risk of ureteric obstruction, Metastatic vertbral lesions and spinal compression Monitor in first few weeks and consider antiandrogens Bone density changes, monitoring patients with prostatic cancer.
Dosages/ Overdosage Etc:
Indications:
Advanced prostatic cancer
Dosage:
Injection- 1mg SC daily.
Use the syringes included in the kit
Patient Information:
1. Do not discontinue medication except on advise of physician
2. Patients should use nonhormonal methods of contraception. Advise patients to see physician , if they believe that they may be pregnant
3. If the patient becomes pregnant during treatment, discontinue the drug and appraise the patient of the potential risk to the fetus.
Pharmacology/ Pharmacokinetics:
Pharmacology:
Leuprolide an LH-RH agonist, is a synthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone with greater potency than the natural hormone. It occupies pitutary receptors and desensitizes them, thus it inhibits gonodatropin secretion when given continously and in therapeutic doses.
Pregnancy and lactation:
Pregnancy:
Leuprolide is contraindicated in women who are or who may become pregnant while receiving the drug.
Lactation:
Do not use during nursing
